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Abstract
Background and Aims
Liver and systemic inflammatory factors influence monocyte phenotype and function, which
has implications for hepatic recruitment and subsequent inflammatory and fibrogenic
responses, as well as host defence.
Methods
Peripheral blood monocyte surface marker (CD14, CD16, CD163, CSF1R, CCR2, CCR4,
CCR5, CXCR3, CXCR4, CX3CR1, HLA-DR, CD62L, SIGLEC-1) expression and capacity
for phagocytosis, oxidative burst and LPS-stimulated TNF production were assessed in
patients with hepatitis C (HCV) (n = 39) or non-alcoholic fatty liver disease (NAFLD) (n = 34)
(classified as non-advanced disease, compensated cirrhosis and decompensated cirrhosis)
and healthy controls (n = 11) by flow cytometry.
Results
The selected markers exhibited similar monocyte-subset-specific expression patterns
between patients and controls. Monocyte phenotypic signatures differed between NAFLD
and HCV patients, with an increased proportion of CD16+ non-classical monocytes in
NAFLD, but increased expression of CXCR3 and CXCR4 in HCV. In both cohorts, mono-
cyte CCR2 expression was reduced and CCR4 elevated over controls. CD62L expression
was specifically elevated in patients with decompensated cirrhosis and positively correlated
with the model-for-end-stage-liver-disease score. Functionally, monocytes from patients
with decompensated cirrhosis had equal phagocytic capacity, but displayed features of dys-
function, characterised by lower HLA-DR expression and blunted oxidative responses.
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Lower monocyte TNF production in response to LPS stimulation correlated with time to
death in 7 (46%) of the decompensated patients who died within 8 months of recruitment.
Conclusions
Chronic HCV and NAFLD differentially affect circulating monocyte phenotype, suggesting
specific injury-induced signals may contribute to hepatic monocyte recruitment and sys-
temic activation state. Monocyte function, however, was similarly impaired in patients with
both HCV and NAFLD, particularly in advanced disease, which likely contributes to the
increased susceptibility to infection in these patients.
Introduction
Monocytes are heterogeneous and highly plastic cells that play critical roles in host defence
and tissue homeostasis. Experimental models demonstrate that peripheral blood monocytes
continuously traffic to (and probably from [1]) the healthy liver, but are recruited in increased
numbers in the setting of liver injury, driving liver inflammation and fibrogenesis [2–5]. We
and others have previously reported elevated numbers of liver monocytes/macrophages from
the early stages of chronic liver disease (CLD) in patients with chronic hepatitis C (HCV) and
non-alcoholic fatty liver disease (NAFLD)[6–8], in the absence of evidence of local prolifera-
tion, supporting a role for infiltrating monocyte-derived macrophages in human disease
progression.
Human monocytes are broadly classified into three phenotypically and functionally dis-
tinct subsets, based on CD14 and CD16 expression; which likely represent different stages
of maturity and differentiation [9]. ‘Classical’ CD14high/CD16- monocytes (comprising
~80% of peripheral blood monocytes) express high levels of chemokine (C-C motif)
receptor (CCR)2 and exhibit strong phagocytic capacity. CD16+ monocytes, which preferen-
tially express the chemokine (C-X3-C motif) receptor (CX3CR)1, were traditionally desig-
nated pro-inflammatory, although recent evidence supports a prominent role for the
CD14highCD16+ ‘intermediate’ subset in inflammation, and angiogenic and surveillance
functions for the CD14+/CD16+ ‘non-classical’ subset [9, 10]. Alterations in monocyte sub-
sets, in particular an increase in intermediate and/or non-classical monocytes, are
frequently observed in infectious and inflammatory diseases, and are associated with
clinical outcomes [10–12]. However the relationship between circulating monocytes and
innate immune-driven disease processes at the site of injury is complex and context
dependent.
Multiple chemokines are reported to be elevated in the liver and serum of patients with
CLD [13, 14] and regional differences in the expression of intrahepatic chemoattractants [15,
16] may be responsible for regional localisation of distinct leukocyte populations [6, 7, 15].
Although a key role for classical monocytes and the CCR2/chemokine (C-C motif) ligand
(CCL)2 axis in driving liver inflammation and fibrogenesis has been demonstrated in mice [2,
4, 5], preferential accumulation of hepatic and, in some studies peripheral, CD16+ monocytes
has been reported in human CLD [8, 11, 17, 18], especially in areas of active inflammation
and fibrosis [19]. Evidence suggests that both enhanced recruitment of CD16+ monocytes and
local differentiation from CD16- precursors contribute to the preferential accumulation of
CD16+ monocytes in the liver [8, 19]. Whether peripheral blood monocyte subsets are altered
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in patients with CLD of different etiologies or at different stages of disease, and how they are
recruited and contribute to disease progression, is not well understood.
In addition to supplying the liver with macrophage and dendritic cell precursors, circulating
monocytes are functional innate immune cells, mediating host defence against microbial path-
ogens through phagocytosis, production of reactive oxygen species (ROS) and inflammatory
and regulatory cytokines. Innate immune dysfunction likely contributes to the high susceptibil-
ity to infection in patients with advanced liver disease [20, 21]. Increased numbers of immuno-
suppressive monocytes were observed in patients with acute on chronic liver failure [22], and
reduced monocyte major histocompatibility complex class II surface receptor (HLA-DR)
(involved in antigen presentation and T-cell activation) levels predicted adverse prognosis and
paralleled disease severity in critically ill patients with cirrhosis [23]. Poor peritoneal monocyte
phagocytic and bactericidal capacity was associated with infection in patients with cirrhosis
and ascites [21], but whether circulating monocyte function is impaired in people with CLD,
and at what stage of disease, has not been widely studied.
The first aim of this study was to characterise the phenotype of circulating monocytes in
patients with chronic HCV infection and NAFLD. We sought to determine whether alterations
in monocyte subsets or chemokine receptor expression are seen in patients with different etiol-
ogies or stages of liver disease, in order to gain insight into the recruitment signals responsible
for hepatic monocyte/macrophage accumulation. The second aim was to assess the function of
circulating monocytes, to determine whether monocyte immunocompetence is impaired with
CLD progression.
Materials and Methods
Patients and clinical data
Non-fasting peripheral blood samples (12 mL) were collected from inpatients or people
reviewed in the hepatology outpatient clinic at the Princess Alexandra Hospital, Brisbane,
Australia. Demographic and clinical characteristics, including complete blood counts and
blood chemistry, and survival data were obtained from research nurse interview and
medical records. Diagnosis of liver disease was based on standard biochemical and serologi-
cal assays. Chronic HCV infection was confirmed by detection of circulating HCV RNA. A
diagnosis of NAFLD required demonstration of hepatic steatosis by imaging or liver biopsy
in the presence of metabolic risk factors and the exclusion of significant alcohol consump-
tion (<10g/day for women and <20g/day for men) and other causes of hepatic steatosis or
other chronic liver disease. Liver disease severity was broadly classified by a hepatologist
(EEP) as “no advanced disease”, “advanced fibrosis” (determined by transient elastography,
liver biopsy if available or liver imaging consistent with cirrhosis and/or portal hyperten-
sion), or “decompensated liver disease” (determined by the presence of ascites, hepatic
encephalopathy, variceal bleeding or jaundice). Patients with non-advanced fibrosis, com-
pensated and decompensated cirrhosis had median fibroscan readings of 6.3, 14.6 and 43,
respectively (data available for 49 patients). Patients with compensated and decompensated
cirrhosis had median model for end stage liver disease (MELD) scores of 8 and 15.5 respec-
tively. Eleven blood samples collected from healthy volunteers matched by age and sex were
used as control samples to obtain non-diseased values. The protocol was approved by The
University of Queensland and Metro South Hospital and Health Services Human Research
Ethics Committees, and written informed consent was obtained from each patient and
volunteer.
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Phenotypic assessment of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-PAQUE (GE Health-
care Life Sciences) as described in the manufacturer’s manual before cryopreservation. Phe-
notyping panels comprised conventional monocyte subset and activation markers and
candidate receptors relevant to liver recruitment, identified by literature search and reanaly-
sis of public microarray data (GSE33650 [24], GSE40184 [25]). 0.5–1x106 cells were resus-
pended in FACS Buffer (PBS/2% FBS/5 mM EDTA) and stained with optimised panels
comprising the following antibodies CD14-BV421 (M5E2), CD163-PerCP-Cy5.5 (GHI/61),
CSF1R-PE (AFS98), CCR4-PerCP-Cy5.5 (L291H4), CCR5-PE (2D7), HLA-DR-FITC (L243),
CXCR3-PE-Cy7 (G025H7), CXCR4-PerCP-Cy5.5 (12G5), CD62L-FITC (DREG-56),
SIGLEC-1-APC (7–239) (all BioLegend), CD16-APC-H7 (3G8; BD Biosciences) and
CCR2-APC (48607; R&D Systems) on ice for 30 minutes in the dark. Each panel included
CD14 and CD16 to identify the 3 main monocyte subsets as well as LIVE/DEAD Aqua
(Molecular Probes) to label non-viable cells. The median fluorescence intensity (MFI) of
each monocyte subset marker was normalized by subtracting the MFI of the corresponding
fluorescence-minus-one control channel (S1 Fig). Unstained, single colour and fluorescence-
minus-one control tubes were performed to generate compensation matrices that correct for
spectral overlap and assist with gating.
Ex vivo functional assays
Monocyte function was assessed in EDTA-coagulated whole blood within 2 hours of collection.
Monocyte phagocytic capacity was assessed by the uptake of pHrodo™ E.coli BioParticles1
(Molecular Probes), which fluoresce in the decreased pH environment of phagosomes. 100μL
of whole blood was incubated with 10μL of 1mg/mL (~3x106 BioParticles) stock for 60 minutes
at 37°C in the presence of monocyte surface marker antibodies, followed by red blood cell lysis
(0.17M NH4Cl/0.001M EDTA/0.01M Tris, pH 7.4) and 2 washes in PBS.
Dichlorodihydrofluorescein diacetate (DCFH-DA; Molecular Probes) was used to assess
monocyte ROS. 100μL of whole blood was loaded with 50μMDCFH-DA, together with mono-
cyte surface marker antibodies for 15 minutes at 37°C. The samples were stimulated for 15
minutes with 200 μg/mL zymosan opsonised with normal human serum (30 minutes at 37°C),
or left unstimulated, followed by red blood cell lysis.
To assess monocyte-specific tumour necrosis factor (TNF) production, 200μL of whole
blood was stimulated with lipopolysaccharide (LPS) (100ng/mL), or left unstimulated, in the
presence of the protein transport inhibitor Brefeldin A (10μg/mL; Sigma) for 4 hours at 37°C,
with the addition of monocyte surface marker antibodies 45 minutes before the end of culture.
Following red blood cell lysis samples were fixed in 4% paraformaldehyde for 5 minutes,
washed in permeabilisation buffer (FACS Buffer containing 0.5% saponin) and stained for
intracellular TNF-APC (MAb11; BioLegend).
All phenotypic and functional assay samples were washed twice in PBS and resuspended in
1% paraformaldehyde for analysis, acquired using Beckman Coulter Gallios flow cytometer
and analysed using Kaluza Analysis Software.
Statistical Analysis
MFI values were log transformed for statistical analysis to normally distribute the data. Statisti-
cal analyses utilised one-way analysis of variance, with Tukey’s or Dunnett’s post-test, the Stu-
dent’s t test and Spearman’s rank-correlation coefficient. A P value of<0.05 was defined as the
level of significance and all graphs and analyses were performed using Graph Pad Prism (ver-
sion 6.04; GraphPad Software Inc.).
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Results
Patient characteristics at venesection
Of a total of 73 patients, 39 patients had chronic HCV and 34 had NAFLD. A cohort of 11 age
and sex-matched healthy volunteers was included to obtain non-diseased values. Demographic
and clinical characteristics of the subjects at the time of venesection are summarised in Table 1.
NAFLD is associated with an increase in peripheral monocyte CD16+
subset regardless of disease stage
To determine whether circulating monocyte subsets are altered in different etiologies or stages
of disease, PBMC were isolated from control subjects and patients with HCV or NAFLD,
stained for monocyte markers CD14 and CD16 and assessed by flow cytometry (Fig 1A).
Automated clinical complete blood cell counts revealed modestly elevated numbers of mono-
cytes in patients with HCV compared to NAFLD (Fig 1B), however this was not observed fol-
lowing PBMC isolation, where the proportion of monocytes within the PBMC fraction was
comparable between control subjects and CLD patients regardless of etiology and stage of dis-
ease (Fig 1C). In our cohort of patients with NAFLD, monocyte subsets were skewed towards
the CD16+ populations with an increase in both intermediate and non-classical subsets and a
commensurate decrease in classical monocytes compared to control subjects, however this
was not seen in patients with HCV (Fig 1D). This increase in the CD16+ monocyte subsets
was not attributed to a specific stage of disease (data not shown). The proportion of mono-
cytes (total or subsets) was not associated with clinical or demographic parameters, including
age, gender, BMI, ALT/AST levels, MELD score, fibroscan result, neutrophil to lymphocyte
ratio or viral genotype.
Reduced monocyte CCR2 expression in HCV and NAFLD
In addition to CD14 and CD16, phenotypic differences between monocyte subsets have been
identified, and related to differences in function [9]. The distribution of expression of our
selected phenotypic markers differed between the three monocyte subsets, and this distribution
was conserved across both patient and healthy cohorts. As expected, monocytes were positive
for the established subset markers CCR2 and CX3CR1 with preferential expression on
CD14high/CD16- classical and CD14+/CD16+ non-classical monocytes respectively, in both
Table 1. Demographic and clinical characteristics of patient cohorts.
HCV NAFLD Healthy controls
No. of patients; n 39 34 11
Age, years; median (range) 57.9 (32.7–67.4) 60.4 (27.4–79.2) 55.5 (24–84)
Gender, male; n (%) 25 (64.1) 19 (55.9) 6 (54.5)
BMI, kg/m2; median (range) 26.7 (18–42.6) 31.4 (22.8–53.5)
Cirrhosis status; n (%)
No advanced fibrosis 16 (41) 11 (32.3) -
Cirrhotic 12 (30.8) 14 (41.2) -
Decompensated 11 (28.2) 9 (26.5) -
Viral Genotype; n (%)
1 a/b 25 (64.1) - -
2 2 (5.1) - -
3 12 (30.8) - -
doi:10.1371/journal.pone.0157771.t001
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control subjects and CLD patients (Fig 2A and 2B). Similarly, HLA-DR, CD163, CCR5 and col-
ony stimulating factor receptor (CSF1R) were highly expressed on CD14high/CD16+ intermedi-
ate monocytes (Fig 2B), although CCR5 and CSF1R were expressed at very low levels (Fig 2A).
Interestingly, in both HCV and NAFLD, monocyte CCR2 expression was significantly lower
when compared to healthy controls (Fig 2C).
Reduced monocyte HLA-DR expression in decompensated cirrhosis
Previous studies have suggested patients with advanced cirrhosis display an “immune paraly-
sis” phenotype, characterised by low HLA-DR expression, contributing to increased mortality
[26, 27]. In our cohort, HLA-DR expression was significantly reduced in patients with HCV-
related decompensated cirrhosis (P<0.01), and similarly reduced in patients with NAFLD,
Fig 1. Peripheral blood monocyte subset distribution in chronic liver disease (CLD). (A) Representative flow cytometry plot of the 3
main monocyte subsets, i—CD14highCD16- “Classical”, ii—CD14highCD16+ “intermediate”, iii—CD14+CD16+ “non-classical”monocytes.
(B) Distribution of peripheral leukocyte lineages obtained from patient haematology full blood counts. (C) Proportion of monocytes in
isolated peripheral blood mononuclear cell (PBMC) in control subjects and CLD patients with no-advanced fibrosis (No adv.), cirrhosis or
decompensated cirrhosis (Decomp). (D) Distribution of monocyte subsets in the PBMC fraction of control subjects and CLD patients. (Data
represented as mean +SEM, ** ++ ## ψψ P<0.01; D, significance shown vs corresponding control subset; Neut, neutrophils; Lymph,
lymphocytes; Mono, monocytes; Eosin, eosinophils; Baso, basophils)
doi:10.1371/journal.pone.0157771.g001
Altered Monocyte Phenotype and Function in Chronic Liver Disease
PLOS ONE | DOI:10.1371/journal.pone.0157771 June 16, 2016 6 / 20
Fig 2. Characterisation of monocyte phenotype in chronic liver disease (CLD). (A) Proportion of monocytes positive for
common subset markers in control subjects and patients with HCV or NAFLD. (B) Level of expression (median fluorescence
intensity, MFI) of selected markers on the 3 main monocyte subsets in patients with HCV. Figures are representative of subset
expression in patient and control cohorts. (C) Monocyte CCR2 and HLA-DR expression in control subjects and CLD patients with
no advanced fibrosis, cirrhosis or decompensated cirrhosis. (Data represented as mean +SEM, * P<0.05, **P<0.01, **P<0.001)
doi:10.1371/journal.pone.0157771.g002
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although this did not reach statistical significance (P = 0.09) (Fig 2C). Elevated levels of soluble
and monocyte CD163 expression have also been reported in acute-on-chronic liver failure
[28], and may be predictive of hospital patient mortality in patients with sepsis [29]. CD163
levels were similar in patients with NAFLD and control subjects, but were positively correlated
with MELD score in patients with HCV (r = 0.53, P = 0.001).
Altered monocyte expression of CCR4, CXCR3, CXCR4 and CD62L in
CLD
To gain further insight into monocyte phenotype in CLD, we selected a panel of markers that, in
addition to CX3CR1 and CCR2, may be involved in monocyte recruitment to the injured liver.
CCR4, a chemokine receptor that was over-expressed in portal areas of patients with HCV, may
recognise several chemokines identified in portal tracts or otherwise implicated in CLD progres-
sion, including CCL4, CCL5, CCL2 [15]. In our cohort, CCR4 was expressed on a variable pro-
portion of monocytes (2–67%), most commonly on intermediate monocytes and a subset of
classical monocytes (Fig 3A and 3B). CCR4 expression was significantly increased in patients
with CLD compared to controls, regardless of disease stage or etiology (Fig 3C). Chemokine
(C-X-C motif) receptor (CXCR)3 is the receptor for chemokines CXCL9-11 and CXCL4 that are
upregulated in HCV infected liver and/or peripheral blood [15, 24, 25], and liver CXCR3 expres-
sion correlated with portal T-cell accumulation [15]. CXCR3 was most highly expressed on
intermediate monocytes (Fig 3B), and significantly increased in patients with HCV, but not
NAFLD, regardless of disease stage (Fig 3C). CXCR4, the receptor for CXCL12, a chemokine
expressed by inflamed biliary epithelium in primary biliary cirrhosis and HCV [16], was
enriched in portal compared to parenchymal regions in HCV patients with advanced fibrosis
[24]. CXCR4 was highly expressed on CD16- monocyte subsets (Fig 3B) and, like CXCR3,
increased in patients with HCV but not NAFLD, regardless of disease stage (Fig 3C).
In addition to chemokine receptors, we investigated the expression of the selectin CD62L
and sialic acid binding Ig-like lectin (SIGLEC)-1 (also known as CD169) as monocyte recruit-
ment is also highly dependent on adhesion molecules. SIGLEC-1 is specifically expressed on
myeloid cells [30], and was among the most highly upregulated genes in HCV PBMC at the
mRNA level [25]. In our cohort, CD14high monocytes displayed higher SIGLEC-1 expression
than the CD14+CD16+ subset (Fig 3B). There was a modest increase in SIGLEC-1 expression
in cirrhotic patients with NAFLD compared to controls, but no alterations in patients with
HCV (Fig 3C). CD62L has been shown to be more highly expressed on inflammatory liver
macrophages compared to restorative macrophages in mouse models of CLD [3] and the corre-
sponding human CD14highCD16- subset also displays high levels of gene expression [31]. In
our cohort, CD62L was most highly expressed on intermediate monocytes (Fig 3B), however a
small proportion of CD62L+ monocytes was observed within each subset suggesting that
CD14+CD62L+ monocytes may represent a unique population, masked by current gating strat-
egies. Monocyte CD62L expression increased in HCV and NAFLD patients with decompen-
sated cirrhosis (Fig 3C). CD62L expression was positively correlated with MELD score in both
HCV and NAFLD cohorts (r = 0.51 P = 0.002 and r = 0.4 P = 0.02, respectively).
Monocytes from patients with CLD have reduced functional capacity
Monocytes have a crucial role in extracellular bacterial and fungal clearance through phagocy-
tosis and oxidative responses. Impaired monocyte function may contribute to susceptibility to
infection observed in end-stage liver disease or prevent effective immune responses during
early stages of disease. Here, phagocytic capacity, oxidative responses and inflammatory
Altered Monocyte Phenotype and Function in Chronic Liver Disease
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Fig 3. Alterations in chemokine receptor expression and adhesionmolecules implicated in monocyte recruitment
in patients with chronic liver disease (CLD). (A) Proportion of monocytes positive for selected chemokine receptors and
adhesion molecules in control subjects and patients with HCV or NAFLD. (B) Level of expression (median fluorescence
intensity, MFI) of selected markers on the 3 main monocyte subsets in patients with HCV. Figures are representative of
subset expression in patient and control cohorts. (C) Expression of selected markers on monocytes from control subjects
and CLD patients with no advanced fibrosis, cirrhosis or decompensated cirrhosis. (Data represented as mean +SEM,
*P<0.05, **P<0.01, ***P<0.001)
doi:10.1371/journal.pone.0157771.g003
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cytokine production were assessed to determine the consequences of persistent hepatic damage
due to viral or metabolic injury.
Monocyte phagocytic capacity for fluorescently labelled E.coli BioParticles was assessed by
flow cytometry (Fig 4A). Greater than 90% of monocytes from control subjects and patients
with CLD phagocytosed FITC-labelled E.coli particles (Fig 4B and 4C), with CD14high mono-
cytes having the largest phagocytic capacity (increased fluorescence intensity)(data not
shown). Monocytes from patients with HCV had a reduced phagocytic capacity compared to
control subjects (P<0.05) (Fig 4D), which was more prominent prior to decompensation (Fig
4E). Monocytes from patients with NAFLD showed a similar trend, but this did not reach sta-
tistical significance (P = 0.2) (Fig 4D and 4E). Monocyte phagocytic capacity was inversely cor-
related with increasing ALT levels (rs = -0.5061 P<0.01) (Fig 4F) but not AST levels (rs =
-0.2763, P = 0.09) in patients with HCV, but not NAFLD (Fig 4G).
Monocyte capacity to generate a microbicidal oxidative burst was assessed by their produc-
tion of ROS in response to serum-opsonised zymosan using the oxidisable fluorescent probe
DCFH-DA (Fig 5A). CD14high and CD14low monocytes had equal capacity to produce ROS.
Fewer monocytes from both HCV (P<0.01) and NAFLD (P<0.05) patient cohorts produced
ROS upon stimulation when compared to control subjects (Fig 5B), which was consistent
across all stages of disease but only reached statistical significance for HCV patients with
decompensated cirrhosis (Fig 5C). The amount of ROS generated by monocytes was also sig-
nificantly blunted (P<0.01) (Fig 5D), regardless of disease stage (Fig 5E). In addition, similar
to phagocytic capacity, ROS generation by monocytes from patients with HCV, but not
NAFLD, inversely correlated with ALT levels (rs = -0.4268 P<0.5) (Fig 5F and 5G).
Inflammatory cytokine production was assessed by intracellular staining for the prototypical
cytokine, TNF, after 4 hours ex vivo stimulation with LPS in the presence of the protein transport
inhibitor Brefeldin A (Fig 6A). In the absence of activating stimuli, monocytes were largely nega-
tive for TNF, with the exception of 3 patients who displayed production in>50% of cells. Upon
stimulation with LPS, the CD14high and CD14low subsets were equally capable of producing TNF
and the percentage of monocytes that responded ranged from 8–95%. The proportion of TNF pro-
ducing monocytes and the level of cytokine produced upon stimulation (fluorescence intensity)
did not differ between control subjects and patients irrespective of stage of disease (Fig 6B and 6E).
Reduced Monocyte TNF production is associated with early mortality in
patients with decompensated cirrhosis
The development of life-threatening infections is a common feature of decompensated cirrho-
sis and is associated with significant patient morbidity and mortality. Having observed features
of monocyte dysfunction in our cohort, we assessed whether monocyte dysfunction was indica-
tive of 6 month mortality specifically in patients with decompensated cirrhosis. Five patients
with decompensated cirrhosis died within 6 months of recruitment, and a further 3 were
deceased by 8 months. Monocyte phagocytic capacity and oxidative responses were not associ-
ated with 6 month mortality (Fig 7A and 7B), however monocyte TNF production in response
to LPS was significantly blunted in patients who died within 6 months of inclusion in the study
(P = 0.01) (Fig 7C). Furthermore, monocyte TNF production positively correlated with time to
death (rs = 0.773, P = 0.05) (Fig 7D) suggesting that dysregulated cytokine production may
contribute to mortality in these patients.
Discussion
Peripheral blood monocytes are recruited to the chronically injured liver where they have a key
role in driving hepatic inflammation and fibrogenesis. Despite their contribution to disease
Altered Monocyte Phenotype and Function in Chronic Liver Disease
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Fig 4. Phagocytic capacity of peripheral bloodmonocytes in patients with chronic liver disease
(CLD). (A) Representative flow cytometry plots highlighting CD14+ monocyte uptake of E.Coli FITC-labelled
BioParticles. The proportion of monocytes undergoing phagocytosis (B and C) and monocyte phagocytic
capacity (D and E) in control subjects and CLD patients with no advanced fibrosis (No adv.), cirrhosis or
decompensated cirrhosis (Decomp). (F and G) Correlation between monocyte phagocytic capacity and
patient serum ALT levels. (Data represented as mean +SEM, * P<0.05, **P<0.01)
doi:10.1371/journal.pone.0157771.g004
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Fig 5. Oxidative burst capacity of peripheral blood monocytes in patients with chronic liver disease
(CLD). (A) Representative flow cytometry plots highlighting CD14+ monocyte generation of free oxygen
radicals at baseline or upon stimulation with opsonised zymosan. The proportion of monocytes capable of
generating reactive oxygen species (B and C) and monocyte capacity to produce ROS (D and E) following
stimulation with opsonised zymosan in control subjects and CLD patients with no advanced fibrosis (No
adv.), cirrhosis or decompensated cirrhosis (Decomp). (F and G) Correlation between monocyte oxidative
burst capacity and patient serum levels. (Data represented as mean +SEM, * P<0.05, **P<0.01,
***P<0.001; DCFH-DA, dichlorodihydrofluorescein).
doi:10.1371/journal.pone.0157771.g005
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Fig 6. Monocyte TNF production in patients with chronic liver disease (CLD). (A) Representative flow
cytometry plots highlighting monocyte specific TNF production at baseline or upon stimulation with LPS. The
proportion of monocytes producing TNF (B and C) and the level of TNF production (D and E) following
stimulation with LPS in control subjects and CLD patients with no advanced fibrosis (No adv.), cirrhosis or
decompensated cirrhosis (Decomp). (Data represented as mean +SEM).
doi:10.1371/journal.pone.0157771.g006
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processes at the site of injury, whether circulatingmonocyte subsets are altered and how they
are recruited in liver disease of diverse etiologies or at different stages of disease remains poorly
understood.
Our data show that monocyte subsets are skewed towards the CD16+ populations, irrespec-
tive of the stage of liver disease or clinico-demographic factors, in patients with NAFLD but
not HCV. A similarly modest increase in CD16+ monocytes was previously observed in a very
large, mixed etiology CLD cohort [18], in hepatitis B [11] and NAFLD [32]. Other studies,
however, failed to find statistically significant differences in peripheral blood monocyte subsets
between CLD patients and healthy controls [8, 17], underscoring the inter-individual variabil-
ity in monocyte populations and relatively small effect size. Increased frequency of CD16+
monocytes has also been demonstrated in obesity, type 2 diabetes, cardiovascular disease and
dyslipidemia, metabolic conditions commonly seen in association with NAFLD [33–35].
Although these studies support a connection between adiposity, inflammation and CD16+
monocytes, it remains unclear whether the alteration in monocyte subsets is a consequence of,
or directly adds to the inflammatory response. Of concern, CD14highCD16+ monocyte counts
independently predicted cardiovascular events in a large patient cohort referred for elective
Fig 7. Monocyte function and 6 monthmortality. Patient survival and monocyte phagocytic capacity (A),
zymosan-stimulated oxidative burst (B) and LPS-stimulated TNF production (C) in combined decompensated
HCV and NAFLD cohorts. (D) Correlation between monocyte LPS-stimulated TNF production and time to
death. (Data represented as mean +SEM, ** P<0.01; DCFH-DA, dichlorodihydrofluorescein).
doi:10.1371/journal.pone.0157771.g007
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coronary angiography (n = 951)[36] and another patient cohort with chronic kidney disease
(n = 438)[37]. Longitudinal clinical outcome studies in people with NAFLD will be important
to determine whether the frequency of CD16+ monocytes is a predictive biomarker for cardio-
vascular disease.
In contrast to NAFLD, HCV patients had a different monocyte phenotypic signature, with
increased expression of CXCR3 and CXCR4 regardless of disease stage. Multiple CXCR3
ligands, including CXCL9, CXCL10 and CXCL11, are products of interferon-stimulated genes,
which may suggest this phenotype is a response to chronic viral infection. Elevated hepatic
CXCR3 expression, and peripheral CXCR3 chemokine levels, have been associated with liver
inflammation and fibrosis in chronic HCV [15, 38]. Although studied in the context of T cell
recruitment to inflamed peripheral tissues, including the liver [39, 40], the role of CXCR3 in
hepatic monocyte recruitment, or activation, is unknown. The CXCL12/CXCR4 axis is also
implicated in lymphocyte recruitment to the liver in chronic HCV, with infiltrating T and nat-
ural killer cells expressing high levels of CXCR4 [41]. However, despite known roles in tissue
injury [42], the CXCL12/CXCR4 axis may have a protective role during inflammation and
injury by promoting liver regeneration and repair or controlling mobilisation of inflammatory
cells from the bone marrow [43]. CXCL12, and the CXCR3 ligands CXCL9-11, are expressed
in inflamed portal tracts [15, 16], suggesting the hypothesis, that these axes contribute to
monocyte recruitment specifically to the portal niche, which contains an abundance of macro-
phages, myofibroblasts and activated hepatic progenitor cells that are associated with CLD pro-
gression [6, 15]. Further studies to assess the expression of CXCR3 and CXCR4 on intrahepatic
monocytes, and their location, will provide further evidence as to the role of these chemokine
axes in liver inflammation and fibrogenesis.
In both chronic HCV and NAFLD, monocyte CCR2 expression was significantly lower
(confirming a previous study [18]) and CCR4 expression was significantly higher compared to
control subjects, regardless of disease stage. Although high levels of the CCR2 ligand, CCL2,
are observed in the serum and liver of patients [13, 14], the contribution of this axis to human
CLD is unclear. The reduction in CCR2 expression may reflect a feedback mechanism to con-
trol monocyte mobilisation and tissue recruitment, in response to the increased ligand or
inflammatory stimuli. This finding corroborates our previous data demonstrating a reduction
in the number of CCR2+ liver macrophages in patients with HCV [7]; and further implicates
the CCR2 axis in human CLD. In mice, genetic deletion or pharmacological inhibition of
CCR2 impaired monocyte infiltration and modestly reduced fibrogenic parameters in a num-
ber of hepatic injury models, although injury often remained significantly elevated over con-
trols [5, 44]. However CCR2, but not CCL2, was dispensable for thioacetamide-induced
monocyte recruitment and subsequent liver injury [2], implicating additional CCL2 receptors,
such as CCR4 [45], which was elevated in our patient cohort, in hepatic monocyte recruitment.
In contrast to CCR2 and CCR4, CD62L, a selectin implicated in preferential recruitment of
blood monocytes to sites of inflammation [46], was specifically increased on monocytes from
patients with decompensated cirrhosis. CD62L expression positively correlated with MELD
score, which may suggest increased hepatic recruitment of inflammatory monocytes exacer-
bates tissue injury in these patients.
In addition to providing insight into hepatic recruitment, circulating monocyte phenotype
may be a valuable indicator of the systemic inflammatory state and monocyte immunocompe-
tence. Monocytes are critical mediators of host defence, and infections are responsible for
much of the morbidity, mortality and resource utilisation in patients with decompensated cir-
rhosis. We demonstrate that monocytes from CLD patients have reduced capacity to produce
ROS in response to zymosan stimulation, regardless of etiology or disease stage. These data
suggest impaired antimicrobial function in the setting of CLD, although increased
Altered Monocyte Phenotype and Function in Chronic Liver Disease
PLOS ONE | DOI:10.1371/journal.pone.0157771 June 16, 2016 15 / 20
susceptibility to infection, which is only clinically manifest in patients with decompensated cir-
rhosis, is undoubtedly multi-factorial.
In line with previous studies [27], we confirmed reduced monocyte HLA-DR expression in
decompensated cirrhosis which would likely impair antigen presentation capacity and adaptive
immune responses. Reduced monocyte HLA-DR levels and inability to recover expression pre-
dicted poor prognosis and paralleled liver disease severity [23], leading to significant interest in
the therapeutic potential of agents that can restore monocyte HLA-DR expression [47].
Reduced monocyte HLA-DR expression and capacity for LPS-stimulated TNF induction,
which was associated with early mortality in our cohort, are hallmarks of innate immune
hyporesponsiveness, or ‘immunoparalysis’, that occurs in septic and other critically ill patients,
rendering them susceptible to infections. In cirrhosis, and particularly decompensated cirrho-
sis, this immunosuppressed state may result from continuous translocation of gut microbes
and microbial products due to increased intestinal permeability, which can cause infections,
but also increase portal pressure, impair liver function and worsen haemostasis [48, 49].
Whether reduced TNF production is simply a biomarker of rapid decline or contributed
directly to the death of these patients, in the context of clinical or sub-clinical infections or
other pathological processes, is not known. The association between TNF production and mor-
tality, but not decompensated cirrhosis per se, might help us to make sense of apparently con-
tradictory reports of increased [50, 51] as well as reduced [26, 27] monocyte TNF production
in cirrhosis. Serum TNF has also been associated with cirrhosis severity, contributing to endo-
thelial activation and hemodynamic disturbance [50]. Although we did not measure serum
TNF in this study it has been suggested, paradoxically, that reduced stimulated TNF produc-
tion can co-exist with high serum TNF levels [52].
Although the persistence of inflammatory macrophages is associated with liver fibrosis,
anti-fibrotic roles for macrophages have also been demonstrated in mouse models, both dur-
ing active fibrogenesis and disease resolution [53, 54]. Macrophage cell therapy is an area of
active investigation, as delivery of mature mouse macrophages (but not their precursors) to
mice with toxin-induced chronic liver disease ameliorated fibrosis by dampening inflamma-
tion and promoting matrix degradation [55]. Injection of human monocyte-derived macro-
phages in a murine fibrosis model similarly led to a reduction in markers of liver injury and
fibrosis, and an increase in markers of liver regeneration [56]. More recently, the feasibility of
using autologous monocyte-derived macrophages as therapy for human CLD was tested,
where circulating monocytes from patients with cirrhosis and healthy control subjects were
shown to differentiate into functionally comparable macrophages [56]. Whether or not mono-
cytes from patients with decompensated cirrhosis, that display features of monocyte dysfunc-
tion, could be restored in vitro into functional macrophages may have important implications
for cell-based therapy.
In summary, the current study highlights distinct differences in monocyte phenotype and
function in patients with chronic HCV and NAFLD and provides insight into how specific
injury-induced signals from the liver may alter peripheral blood monocyte phenotype. The
relationship between circulating monocyte phenotype and intrahepatic monocyte/macrophage
phenotype, localisation and function is not clear; it is not known whether distinct monocyte
subsets are recruited to fulfil site-specific functions in CLD or whether circulating monocytes
are recruited indiscriminately and alter their phenotype and function in response to the injured
microenvironment. These are important questions to answer, as altering the recruitment of
specific etiology-dependent monocyte subsets or delivering specific monocyte/macrophage
populations are appealing targets for anti-fibrotic therapies in patients with CLD. Furthermore,
understanding how the balance between monocyte immunosuppressive and immunoprotec-
tive phenotypes effects patient clinical outcomes may aid in the management of end-stage liver
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disease and provide novel therapeutic targets to restore monocyte function to reduce suscepti-
bility to infection.
Supporting Information
S1 Fig. Representative histograms of phenotypic marker expression on classical CD14
+CD16- and non-classical CD14+CD16- on peripheral blood monocyte subsets.Monocytes
were gated based on forward/side scatter properties and CD14/CD16 expression. Median fluo-
rescence intensities (MFI) of selected phenotypic markers were normalized by subtracting the
MFI of the corresponding fluorescence-minus-one control channel.
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